CCND1 Antibodies

The Cyclin D1 (CD1) protein is a crucial regulator of cell cycle progression, encoded by the CCND1 gene on chromosome 11q13. It consists of 295 amino acids, resulting in a molecular weight of approximately 34 kDa. CD1 undergoes various post-translational modifications, including phosphorylation, glycosylation, and ubiquitination, which dynamically regulate its activity. Primarily an intracellular protein, CD1 functions as a key component of the cell cycle machinery, facilitating the transition from the G1 phase to the S phase by activating cyclin-dependent kinases (CDKs) and is a known cyclin and mantle cell marker. 

Its expression is observed in various organs and tissues, notably in proliferating breast, lung, colon, and prostate cells. Extracellular signals, such as growth factors and mitogens, tightly regulate the expression of CD1. The dysregulation of CD1 expression or mutations in the CCND1 gene have been associated with numerous cancers, including breast, lung, and esophageal cancers. 

Cyclin D1 expression serves as a diagnostic and prognostic marker in certain malignancies, aiding in patient management and treatment decisions. Detecting Cyclin D1 expression in tumor tissues can aid in the classification of certain malignancies, particularly in hematological and solid tumors. CD1 overexpression is also a hallmark of mantle cell lymphoma (MCL), and its detection in lymph node biopsies can help differentiate MCL from other types of non-Hodgkin lymphomas. Similarly, Cyclin D1 expression in breast cancer tissues may indicate a specific subtype, such as the luminal B subtype, which has implications for treatment selection. Regarding prognosis, CD1 expression in tumors has been correlated with aggressive tumor behavior, increased risk of disease recurrence, and poorer overall survival in breast and esophageal cancers. On the other hand, low or absent CD1 expression may indicate a more favorable prognosis in certain malignancies. 

NeoBiotechnologies offers a variety of antibodies against CD1 that have been validated for ELISA, flow cytometry, immunofluorescence, immunohistochemistry, and Western blotting, as well as HuProt-validated option. Additionally, we hold exclusive rights to CD1 antibodies available for licensing or collaboration [https://www.neobiotechnologies.com/gene-name/ccnd1/].

Synonyms

G1/S-specific cyclin-D1, BCL1|D11S287E|PRAD1|U21B31

Research Areas

Apoptosis, Autophagy, Breast Cancer, Cancer, Cardiovascular, Cell Biology, Cellular Markers and Tags, Developmental Biology, Endocrine, Epigenetics, Gastrointestinal Tract, Hypoxia, Immuno Oncology, Immunology, Kidney, Lymphatic, Metabolism, Microbiology, Muscle, Neuroscience, Pancreatic Cancer, Prostate Cancer, Skin, Stem Cell, AKT Signaling, Angiogenesis, Articular Cartilage Extracellular Matrix, B Cell Markers, Basal Cell Marker, BBB VCAM-1 Signaling, Bladder Cancer, Cardiac Stem Cells, Colon Cancer, Colorectal Cancer, Complement System, CTLA-4 blockade immunotherapy, Cytokine Signaling, Defective Intrinsic Apoptosis, Dendritic Cell Marker, Digestion, Endothelial Cell Marker, Hematopoietic Stem Cells, Immune checkpoint, Infectious Disease, Lipid Metabolism, Lung Cancer, MAPK Signaling, Mast Cell Marker, Melanoma, Mesenchymal Stem Cell Differentiation, Mitochondria Marker, Neural Stem Cells, Neuroinflammation, Nuclear Marker, Oncology, Ovarian Cancer, PD-1 blockade immunotherapy, Signal Transduction, Stem Cell Differentiation, Transcription Factors